2020 Annual Business Report

2020 Highlights

In 2020, Valneva achieved several major milestones, further enhancing its unique value proposition.

2020  Highlights

A specialty vaccine company

R&D

Lyme disease vaccine candidate VLA15

  • Valneva and Pfizer announced a collaboration to co-develop and commercialize VLA15
  • VLA15 delivered positive initial results for two Phase 2 trials
  • Valneva announced the acceleration of the pediatric development for VLA15

Chikungunya vaccine candidate VLA1553

  • Phase 3 clinical study for VLA1553 initiated
  • VLA1553 was awarded EMA Prime designation
  • Partnership with Instituto Butantan on VLA1553 for Low- and Middle-Income Countries (LMIC)

COVID-19 vaccine candidate VLA2001

  • Valneva and Dynavax entered into a commercial supply agreement to advance an inactivated, adjuvanted COVID-19 vaccine, VLA2001
  • Major COVID-19 vaccine collaboration with the UK government for the supply of up to 190 million doses of VLA2001
  • Phase 1/2 clinical study of VLA2001 initiated

Strategic

  • Valneva shareholders approved EGM Resolutions to support a potential US IPO
  • New $85 Million financing arrangement with leading US healthcare funds Deerfield and OrbiMed

Commercial

  • New IXIARO® supply contract with the US Government worth up to $166 million
  • The FDA approved IXIARO® shelf life extension to 36 months
  • Valneva and Bavarian Nordic announced a marketing and distribution partnership
  • Expansion of commercial operations with the opening of its French commercial office

Organizational

  • Appointment of Juan Carlos Jaramillo as Chief Medical Officer
  • Appointment of Ms. Johanna Willemina Pattenier, MD, PhD and Ms. Sharon Elizabeth Tetlow, MBA as new Supervisory Board Members